Edition:
United Kingdom

Spring Bank Pharmaceuticals Inc (SBPH.OQ)

SBPH.OQ on NASDAQ Stock Exchange Capital Market

14.23USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$14.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,876
52-wk High
$18.93
52-wk Low
$8.47

Chart for

About

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The... (more)

Overall

Beta: --
Market Cap(Mil.): $208.23
Shares Outstanding(Mil.): 12.70
Dividend: --
Yield (%): --

Financials

  SBPH.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.44 -- --
ROI: -61.33 1.58 14.38
ROE: -73.77 2.41 16.07

BRIEF-Spring Bank Pharma Appoints Timothy Clackson To Board

* SPRING BANK PHARMACEUTICALS APPOINTS TIMOTHY CLACKSON, PH.D., TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

05 Mar 2018

BRIEF-Spring Bank Pharmaceuticals Reports Q4 Loss Per Share $0.11

* SPRING BANK PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATIONAL RESULTS

20 Feb 2018

BRIEF-Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial

* Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial

15 Nov 2017

Earnings vs. Estimates